Who Supplies Lactulose to India from GERMANY

Importing finished pharmaceutical formulations containing Lactulose into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, as defined under Rule 122E, prior approval is necessary before importation. Applications for registration and import must be submitted to the Drugs Controller General (I) at CDSCO. The registration process involves submitting detailed documentation, including manufacturing licenses, product composition, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews.

Imported finished pharmaceutical formulations containing Lactulose must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for German manufacturers.

India imports finished Lactulose formulations primarily due to the availability of patented or branded products, specific dosage forms not produced domestically, and the need to meet therapeutic demands. The domestic capacity for Lactulose formulations is limited, leading to a dependency on imports to fulfill market requirements. The market size for Lactulose formulations in India is substantial, with a total export market of $13.4 million across 154 exporters to 90 countries, indicating a significant demand.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Social Welfare Surcharge (SWS) of 10%. Additionally, the Integrated Goods and Services Tax (IGST) is applicable, with rates varying based on the specific product classification. There are no anti-dumping duties or exemptions applicable to this product category. The total landed duty percentage varies depending on the IGST rate but is approximately 17.10% plus the applicable IGST.

India sources finished Lactulose formulations from Germany due to the country's competitive advantages, including the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Germany's share in the Indian market is notable, with a total import value of $148 across two shipments, indicating a strong presence. Other suppliers, such as China and the United States, also contribute to the market, but Germany's reputation for quality and innovation provides a unique advantage.

India imports Lactulose formulations from Germany due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. German manufacturers offer products that meet the specific therapeutic needs of the Indian market, which are not always met by domestic producers.

Compared to other origins like China, the European Union, and the United States, Germany offers superior quality, regulatory compliance, and reliability in pharmaceutical manufacturing. German products are known for their adherence to stringent quality standards, making them a preferred choice for Indian importers seeking high-quality Lactulose formulations.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. While past shortages have been minimal, it is advisable for importers to diversify their supplier base and maintain adequate inventory levels to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO, including submission of Form 40/41.
3. 3Drug Import License: Apply for a license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): Obtain NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs house agent for clearance.
6. 6Advance Ruling: Seek advance ruling for HS Code 30049099 to confirm duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Issued by relevant authorities.
4. 4Drug Master File (DMF): Providing detailed product information